Smac Mimetics for Apoptosis Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug discovery efforts face challenges in identifying effective compounds that inhibit Inhibitors of Apoptosis Proteins (IAPs), which are implicated in cancer and autoimmune diseases, as existing IAP inhibitors may not adequately modulate apoptosis, leading to resistance in tumor cells.
Innovation Solution
Development of Smac mimetics, specifically compounds of Formula (I) and their pharmaceutically acceptable salts, which act as IAP inhibitors by mimicking the interactions of Smac to modulate apoptosis, potentially overcoming resistance in cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing IAP inhibitors are used, then apoptosis modulation is achieved, but tumor cell resistance develops reducing therapeutic efficacy
Solution Approach 1:
The patent employs Smac mimetics that copy the critical functional features of endogenous Smac protein. The compounds contain a Smac-like N-terminal region with the conserved AVPI motif that directly binds to IAP proteins (XIAP, cIAP1, cIAP2), replicating Smac's ability to activate caspases and induce apoptosis. This copying approach overcomes tumor resistance by providing a more potent and specific IAP inhibition mechanism compared to existing inhibitors
Solution Approach 2:
The invention modifies molecular parameters by designing peptides with optimized sequences based on Smac's N-terminal region. The compounds feature specific amino acid substitutions and modifications (e.g., replacing certain residues with D-amino acids or non-natural amino acids) that enhance binding affinity to IAP proteins while improving metabolic stability and cellular permeability, thereby overcoming resistance to conventional IAP inhibitors
2Reliability
If Smac mimetics are developed to overcome resistance, then compound complexity increases, but therapeutic potential improves
Solution Approach 1:
The patent extracts only the essential functional elements required for IAP inhibition from the full-length Smac protein. Specifically, it utilizes the N-terminal 15-amino acid region containing the AVPI motif, which is sufficient for high-affinity binding to IAP proteins. This extraction simplifies the overall molecular complexity while retaining the core therapeutic mechanism, avoiding the need to incorporate the entire Smac sequence or multiple functional domains
Solution Approach 2:
The Smac mimetic compounds are designed as segmented structures with distinct functional regions: an N-terminal region (residues 1-15) that binds IAP proteins, a central region that can be modified for stability, and a C-terminal region that may include cell-penetrating sequences or conjugation sites. This segmentation allows independent optimization of each region's function while maintaining overall therapeutic efficacy
Data Source
AI summary
The present invention describes compounds, processes for their preparation, pharmaceutical compositions containing them, and their use in therapy.